| The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis K Dheda, T Gumbo, G Maartens, KE Dooley, R McNerney, M Murray, ... The lancet Respiratory medicine 5 (4), 291-360, 2017 | 672 | 2017 |
| Global tuberculosis drug development pipeline: the need and the reality Z Ma, C Lienhardt, H McIlleron, AJ Nunn, X Wang The Lancet 375 (9731), 2100-2109, 2010 | 530 | 2010 |
| High-dose rifapentine with moxifloxacin for pulmonary tuberculosis A Jindani, TS Harrison, AJ Nunn, PPJ Phillips, GJ Churchyard, ... New England Journal of Medicine 371 (17), 1599-1608, 2014 | 483 | 2014 |
| Serum drug concentrations predictive of pulmonary tuberculosis outcomes JG Pasipanodya, H McIlleron, A Burger, PA Wash, P Smith, T Gumbo The Journal of infectious diseases 208 (9), 1464-1473, 2013 | 476 | 2013 |
| Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients H McIlleron, P Wash, A Burger, J Norman, PI Folb, P Smith Antimicrobial agents and chemotherapy 50 (4), 1170-1177, 2006 | 323 | 2006 |
| Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome H McIlleron, G Meintjes, WJ Burman, G Maartens The Journal of infectious diseases 196 (Supplement_1), S63-S75, 2007 | 307 | 2007 |
| Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears AH Diacon, RF Patientia, A Venter, PD Van Helden, PJ Smith, H McIlleron, ... Antimicrobial agents and chemotherapy 51 (8), 2994-2996, 2007 | 225 | 2007 |
| Research capacity. Enabling the genomic revolution in Africa. C Rotimi, A Abayomi, A Abimiku, VM Adabayeri, C Adebamowo, ... Science (New York, NY) 344 (6190), 1346-1348, 2014 | 212 | 2014 |
| Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption JJ Wilkins, RM Savic, MO Karlsson, G Langdon, H McIlleron, G Pillai, ... Antimicrobial agents and chemotherapy 52 (6), 2138-2148, 2008 | 189 | 2008 |
| Enabling the genomic revolution in Africa: H3Africa is developing capacity for health-related genomics research in Africa H3Africa Consortium Science (New York, NY) 344 (6190), 1346, 2014 | 184 | 2014 |
| The SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications E Chigutsa, ME Visser, EC Swart, P Denti, S Pushpakom, D Egan, ... Antimicrobial agents and chemotherapy 55 (9), 4122-4127, 2011 | 159 | 2011 |
| Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis E Chigutsa, JG Pasipanodya, ME Visser, PD Van Helden, PJ Smith, ... Antimicrobial agents and chemotherapy 59 (1), 38-45, 2015 | 142 | 2015 |
| Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines H McIlleron, M Willemse, CJ Werely, GD Hussey, HS Schaaf, PJ Smith, ... Clinical Infectious Diseases 48 (11), 1547-1553, 2009 | 142 | 2009 |
| The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis FA Sirgel, PB Fourie, PR Donald, N Padayatchi, R Rustomjee, J Levin, ... American journal of respiratory and critical care medicine 172 (1), 128-135, 2005 | 135 | 2005 |
| Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting GU Van Zyl, TE Van Mens, H McIlleron, M Zeier, JB Nachega, E Decloedt, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 56 (4), 333-339, 2011 | 133 | 2011 |
| Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients JJ Wilkins, G Langdon, H McIlleron, G Pillai, PJ Smith, USH Simonsson British journal of clinical pharmacology 72 (1), 51-62, 2011 | 131 | 2011 |
| Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis Y Ren, JJC Nuttall, C Egbers, BS Eley, TM Meyers, PJ Smith, G Maartens, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 47 (5), 566-569, 2008 | 128 | 2008 |
| GeneXpert MTB/Rif to diagnose tuberculous meningitis: perhaps the first test but not the last NC Bahr, S Marais, M Caws, R Van Crevel, RJ Wilkinson, JS Tyagi, ... Clinical Infectious Diseases 62 (9), 1133-1135, 2016 | 126 | 2016 |
| Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines H McIlleron, R Rustomjee, M Vahedi, T Mthiyane, P Denti, C Connolly, ... Antimicrobial agents and chemotherapy 56 (6), 3232-3238, 2012 | 119 | 2012 |
| Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis K Cohen, G van Cutsem, A Boulle, H McIlleron, E Goemaere, PJ Smith, ... Journal of antimicrobial chemotherapy 61 (2), 389-393, 2008 | 118 | 2008 |
